New hepatitis b drug shows promise in first human tests
NCT ID NCT07595159
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called BW-20507 in 32 people. First, healthy volunteers received a single dose to check safety. Then, people with chronic hepatitis B received multiple doses to see how the drug behaves in the body and whether it fights the virus. The main goal was safety, not effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BW-20507 (an experimental drug given as an injection)
What this could lead to
If successful, this could point toward a new treatment option for chronic hepatitis B, potentially helping control the virus long-term.
What could go wrong
This is a very early Phase 1 trial with only 32 participants, focused on safety. It is too small and early to know if the drug works or is safe for wider use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Argo Investigative Site
Beijing, Beijing Municipality, 100050, China
-
Argo Investigative Site
Chongqing, Chongqing Municipality, 404000, China
-
Argo Investigative Site
Guanzhou, Guangdong, 510700, China
-
Argo Investigative Site
Xuzhou, Jiangsu, 221000, China